Opsona Therapeutics

Opsona Therapeutics was a drug development company specialising in the human immune system and new drugs and vaccines to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases.[1][2][3]

Opsona Therapeutics
Headquarters,
Republic of Ireland 
Websitewww.opsona.com

Based in Ireland, Opsona was a spin-out from Trinity College Dublin (TCD).[4] Ireland is ranked highly in the world in immunology research, and TCD has been at the forefront of the field.[5]

Opsona's research was primarily focused on the role of Toll-like receptors (TLRs) and TLR signalling in human innate immunity. The company was founded in 2004 by three immunologists:

The company went into liquidation in 2019 after unsuccessful clinical trials and failure to find a buyer for OPN-305.

Opsona's main investors were international and life-science focused:

  • Inventages Venture Capital (Bahamas)[9]
  • Seroba Bioventures (Ireland)
  • GenenFund (United States)
  • Enterprise Ireland (Ireland)[10]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.